Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US
Novo Nordisk finally won US approval for its hemophilia drug Alhemo following the product’s rejection by the FDA last year.
The once …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
